<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Ocular Nanomedicine &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/ocular-nanomedicine/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 27 Oct 2025 21:41:22 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Ocular Nanomedicine &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Nanoparticle Bevacizumab Improves Retinopathy in Mice</title>
		<link>https://bioengineer.org/nanoparticle-bevacizumab-improves-retinopathy-in-mice/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Oct 2025 21:40:53 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Anti-VEGF Therapy]]></category>
		<category><![CDATA[Intravitreal Drug Delivery]]></category>
		<category><![CDATA[Nanoparticle Bevacizumab]]></category>
		<category><![CDATA[Nanoparticle drug delivery]]></category>
		<category><![CDATA[Ocular Nanomedicine]]></category>
		<category><![CDATA[pediatric ophthalmology advancements]]></category>
		<category><![CDATA[Retinopathy of Prematurity]]></category>
		<category><![CDATA[retinopathy of prematurity treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/nanoparticle-bevacizumab-improves-retinopathy-in-mice/</guid>

					<description><![CDATA[In a groundbreaking advancement in pediatric ophthalmology, researchers have unveiled a novel therapeutic strategy that significantly mitigates retinal vasculopathy associated with retinopathy of prematurity (ROP) in an in vivo mouse model. This innovative approach leverages the efficacy of intravitreal bevacizumab nanoparticles, presenting a promising horizon for managing one of the leading causes of childhood blindness [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287408</post-id>	</item>
	</channel>
</rss>
